Intermediate conductance calcium-activated potassium channel protein 4 (KCNN4) (KCNN4)

The erythrocyte potassium channel, primarily represented by the Gardos channel (Intermediate conductance calcium-activated potassium channel protein 4 or KCNN4), is a critical regulator of red blood cell volume and hydration [1, 2]. It is activated by increases in intracellular calcium, which triggers the efflux of potassium ions and water, leading to cell shrinkage [2, 5]. In sickle cell disease, the polymerization of hemoglobin S causes membrane damage and calcium influx, leading to chronic overactivation of this channel [2, 4]. This overactivation results in the formation of dense, dehydrated erythrocytes that are highly susceptible to sickling and hemolysis [3, 4]. Consequently, KCNN4 has been identified as a therapeutic target to prevent erythrocyte dehydration and improve the rheological properties of blood in sickle cell patients [3]. Pharmacological inhibitors like senicapoc have been developed to block this channel, successfully increasing hemoglobin levels and reducing hemolytic markers in clinical trials [3, 4]. However, these inhibitors have struggled to meet primary endpoints related to the frequency of vaso-occlusive crises, suggesting a complex role in disease pathology [3]. Beyond sickle cell disease, the channel is also implicated in hereditary xerocytosis and may play a role in the lifecycle of the malaria parasite [1, 5]. The channel is also expressed in other tissues, including T-lymphocytes and secretory epithelia, which raises considerations for potential off-target effects during systemic inhibition [1, 3].

Other names

Gardos channelKCa3.1IK1SK4hKCa4hIK1hSK4Calcium-activated potassium channel subunit 4

Inhibition of the channel to prevent the efflux of potassium and water, thereby maintaining erythrocyte hydration and preventing cell sickling.